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Elecsys® AMHObjectives: Anti-Müllerian hormone (AMH) is an established biomarker for assessing ovarian reserve and
predicting response to controlled ovarian stimulation. Its routine clinical use is hampered by the variability and
low-throughput of available enzyme-linked immunosorbent assays (ELISA). The presented study examined if a
fully automated AMH electrochemiluminescence assay (ECLIA; Elecsys® AMH assay, Roche Diagnostics) was suit-
able for measuring AMH levels in healthy women and in those diagnosed with polycystic ovary syndrome (PCOS).
Design andmethods: Five European laboratories evaluated the Elecsys® AMH assay independently under rou-
tine conditions over eightmonths.Within-run imprecision, repeatability, intermediate precision, linearity and func-
tional sensitivity were assessed. The Elecsys® AMH assay was compared to a manual ELISA microtiter plate format
test (AMHGen II ELISA,modiﬁed version; Beckman Coulter Inc.) using 1729 routine serum samples. AMH reference
intervals were determined in 887 healthy womenwith regular menstrual cycle aged 20–50 years, and 149 women
diagnosed with PCOS.
Results: The fully automated Elecsys® AMH assay showed excellent precision, linearity, and functional
sensitivity. The coefﬁcient of variationwas 1.8% for repeatability and 4.4% for intermediate precision. Values
measured with the Elecsys® AMH assay were highly correlated with the manual ELISA method (modiﬁed
version) but 24–28% lower. Reference intervals showed the expected AMH decline with age in healthy
women and increased AMH levels in women with PCOS.
Conclusions: The Elecsys® AMH assay demonstrated good precision under routine conditions, and is
suitable for determining AMH levels in serum and lithium-heparin plasma.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Anti-Müllerian hormone (AMH) is a dimeric glycoprotein that
belongs to the transforming growth factor β family [1]. In women,
AMH is produced by ovarian granulosa cells of pre-antral and small
antral follicles and is involved in the control of ovarian follicle growth; COH, controlled ovarian
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iety of Clinical Chemists. Publisthrough paracrine and autocrine effects [2–4]. Serum AMH is associated
with ovarian response to controlled ovarian hyperstimulation (COH),
and is also associated with gonadotropin dose adjustments [5]. AMH
levels correlate with antral follicle count (AFC) and increasing evidence
suggests that AMH is currently the best available test for ovarian reserve
assessment [6,7]. Furthermore, AMH offers the convenience of simple
blood sampling and AFC is prone to considerable operator-dependent
variability [8]. A recent large prospective, non-randomized study
suggested that an AMH-based treatment approach for COH may result
in reduced treatment burden and reduced risk for hyper-response
with maintained pregnancy rates [9]. Moreover, inter- and intra-cycle
variations are low for AMH, reﬂecting the non-cyclic (follicle-stimulating
hormone [FSH]-independent) growth of pre-antral and small antral
follicles [10,11]. Therefore, serum AMH measurement is both a reliablehed by Elsevier Inc. This is an open access article under the CC BY license
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ward and consistent serum AMH measurements are necessary for
optimal assessment of the ovarian reserve.
The 2013 National Institute for Health and Care Excellence (NICE)
clinical guideline for fertility and the European Society of Human Repro-
duction and Embryology (ESHRE) recommend AMH measurement as
one method to predict ovarian response to gonadotropin stimulation
[12,13]. The NICE guideline states that AMH concentration of ≤0.75
ng/ml (≤5.4 pmol/L) indicates a low ovarian response to stimulation,
whereas AMH concentration ≥3.50 ng/ml (≥25.0 pmol/L) indicates a
high response [12]. It follows that precise and accurate AMH measure-
ment in these intervals is a prerequisite for reliable interpretation of
AMH results in a clinical setting. However, limited assay reproducibility
(precision) was observed with the AMH Gen II ELISA assay, unmodiﬁed
version (Beckman Coulter) [14–16]. Beckman Coulter modiﬁed the
assay to include a pre-dilution step to avoid interference from com-
plement binding (AMH Gen II ELISA, modiﬁed version). Manual im-
munoassay techniques are labor-intensive, time-consuming and
subject to the inﬂuence of handling techniques on results, making
them less reproducible than fully automated assays. Therefore, there
is a need for a precise and reliable fully automated AMH assay [6].
Recently, the ﬁrst fully automated AMH electrochemiluminescent
immunoassay (‘ECLIA AMH’, Elecsys® AMH assay, Roche Diagnostics)
was developed and an initial analytical evaluation of the assay found
no evidence for sample instability or variability [17].
Other studies on the Elecsys®AMH assay that included an analytical
performance evaluation reported the intra-assay precision only [18] or
linearity, within-run and intermediate precision based on a 10-day
experiment [19] without speciﬁcation of the immunoanalyzers used.
The aim of the present study was to perform a thorough analytical
evaluation of the automated Elecsys® AMH assay with an assessment
of within-run imprecision, 21-day repeatability and intermediate preci-
sion, linearity and functional sensitivity onMODULAR ANALYTICS E 170,
cobas e 411 and cobas e 601 immunoanalyzers in a large multicenter
study.
In addition, appropriate age-speciﬁc reference interval values were
established for this assay in a large female population, as no international
reference material for AMH is yet available. Women with regular
menstrual cycles andwomendiagnosedwith polycystic ovary syndrome
(PCOS) were included in this study for reference interval determination.
PCOS is the most common endocrinopathy among women of reproduc-
tive age and is characterized by a combination of menstrual cycle
dysfunction, hyperandrogenism, and polycystic ovary morphology
(≥12 antral follicles per whole ovary) [20,21]. An increased number of
antral follicles is a prevailing element within PCOS, therefore these
women were included in the current study to assess the Elecsys® AMH
assay in this patient population.
2. Materials and methods
2.1. Investigational sites
The multicenter evaluation of the analytical performance of the
Elecsys® AMH assay was conducted from May 2013 to December
2013 at ﬁve laboratories: UZ Brussels, Free University of Brussels (VUB),
Belgium; Duzen Laboratories, Ankara, Turkey; Laboratoire Eylau, Paris,
France; Limbach Laboratory, Heidelberg and MVZ wagnerstibbe für
Laboratoriumsmedizin and Pathologie GmbH, Hannover, Germany.
Each laboratory routinely used ELISA testing for quantiﬁcation of AMH.
2.2. Study design
The study design of the multicenter evaluation comprised within-
run precision and method comparison experiments conducted at ﬁve
different laboratories on one MODULAR ANALYTICS E 170, three
cobas e 411 and two cobas e 601 immunoanalyzers. In addition, attwo laboratories, repeatability and total imprecision according to
CLSI EP5 protocol and testing of the functional sensitivity and linearity
of the assay were performed onMODULAR ANALYTICS E 170 (n = 1),
cobas e 411 (n = 1) and cobas e 601 (n = 1) systems. Furthermore,
reference intervals were determined on one MODULAR ANALYTICS E
170, cobas e 411 and cobas e 601 immunoanalyzers using two different
AMH assay reagent lots.
Within the context of the performance evaluation of Elecsys® AMH
assay a reference interval study was initiated in a population of appar-
ently healthy women and in women diagnosed with PCOS. Reference
intervals were determined in at least two independent runs using one
cobas e 411, one MODULAR ANALYTICS E 170 and one cobas e 601
analyzer as the measurement devices and two different AMH reagent
lots per instrument. Each run was calibrated with AMH CalSet and vali-
dated by a quality controlmeasurementwith PreciControl AMH1 and 2,
prior to each experimental run.
The Elecsys® AMH was calibrated using two calibration levels of
AMH CalSet (Roche Diagnostics GmbH, Germany, catalog number
06331084 190). Each run was validated by measuring two levels of
quality control material (Elecsys® PreciControl AMH 1 and 2 assay,
Roche Diagnostics GmbH, Germany, catalog number 06709966 190)
prior to starting the experiment. The assaywas standardized to be trace-
able to AMH Gen II ELISA (Beckman Coulter Inc., USA, catalog number
A79765/A79766, unmodiﬁed version).
Reference intervals were determined for PCOS subjects aging from
18 to 43 years. For reference interval determination of the apparently
healthy female sample set including women from 20 to 50 years, six
cohorts were established, each spanning an age range of ﬁve years.
All sample sets were equally distributed among the three study
instruments and measured in a randomized order.
2.3. Ethical approval
All investigation and sample collection sites followed International
Conference on Harmonization guideline for Good Clinical Practice E6
and conducted the study in accordance with the Declaration of Helsinki
(as amended in Tokyo, Venice, Hong Kong, and Edinburgh). Where
required, Ethics Committee approval of the respective institutions was
obtained. The reference interval study included samples only from
subjects who signed an informed consent agreement.
2.4. Statistical methods
Measurements were captured using the WinCAEv software [23].
Reference intervals were determined in accordance with the
International Federation of Clinical Chemistry recommendations
[22]. For sample cohorts 2.5%, 5%, 95% and 97.5% non-parametric percen-
tiles were calculated (with 95% CI according to the method of Hahn and
Meeker [24]). No outlier detection method was used when analyzing
the data. All statistical analyses were performed using R Version 3.0.1.
2.5. Assay procedure
The fully automated AMH assay is an electrochemiluminescence
immunoassay for use on Elecsys® and cobas e immunoassay analyzers
(manufactured by Roche Diagnostics GmbH, Germany, catalog number
06331076 190) [17].
The test design corresponds to a sandwich immunoassay, based on
the streptavidin-biotin-technology. The capture antibody is biotinylated,
the detection antibody is covalently linked with a Ruthenium complex.
Successfully formed antigen-antibody complexes can be detected via
electrochemiluminescence within a total assay time of 18 min.
The fully automated Elecsys® immunoassay detects AMH in the
range of 0.01 to 23 ng/ml (0.07 to 164 pmol/L) and requires 50 μl of
serum or lithium-heparin plasma.
Fig. 1.Within-run precision CV for spiked serum samplematerial atﬁve levels covering the entiremeasuring range. Each sample level was analyzed 21 times in a single analytical run on a
MODULAR ANALYTICS E 170, cobas e 411 and cobas e 601 systems. The gray bar indicates the mean CV among all instruments.
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All study sites evaluated the Elecsys® AMH performance indepen-
dently using male fetal bovine spiked serum samples and routine serum
samples. Left-over routine serum samples for the method comparison
experiment were aliquoted and stored at−20 °C. Spiked serum sample
material was stored at−20 °C until measurement. Sampleswere thawed
shortly before measurement. For long term storage of reference intervalTable 1
Repeatability and intermediate precision CV for ﬁve spiked serum samples and two quality
control samplematerials (PreciControl AMH1 and 2) at levels covering the entiremeasuring
range. Repeatability and intermediate precision were determined over 21 days measuring
each sample induplicateduring two runsper day (n=84) according toCLSI EP5-A2protocol
on theMODULAR ANALYTICS E 170 analyzer, cobas e 411 and cobas e 601 systems.
Instrument Mean
(ng/mL)
Mean
(pmol/L)
Repeatability
CV (%)
Intermediate
precision CV (%)
cobas e 601 1.22 1.80
cobas e 411 0.24 1.72 1.79 4.37
MODULAR ANALYTICS E 170 1.68 3.24
cobas e 601 1.04 1.78
cobas e 411 0.72 5.14 1.07 3.97
MODULAR ANALYTICS E 170 1.23 2.67
cobas e 601 1.09 2.15
cobas e 411 1.14 8.14 1.00 2.87
MODULAR ANALYTICS E 170 1.17 3.53
cobas e 601 0.92 1.59
cobas e 411 2.47 17.63 1.22 3.35
MODULAR ANALYTICS E 170 1.08 2.73
cobas e 601 1.10 2.23
cobas e 411 5.70 40.70 1.00 3.77
MODULAR ANALYTICS E 170 0.93 3.40
cobas e 601 1.07 1.90
cobas e 411 12.58 89.82 1.07 3.66
MODULAR ANALYTICS E 170 1.26 3.05
cobas e 601 1.43 1.83
cobas e 411 19.04 136 1.53 3.79
MODULAR ANALYTICS E 170 0.96 3.32samples, aliquots of PCOS samples were kept frozen at−20 °C, healthy
subject samples at−80 °C for less than two years.2.7. Within-run imprecision
The study sponsor provided each laboratory with spiked serum
sample material in ﬁve levels covering the entire measuring interval.
Each sample level was analyzed 21 times in one analytical run. Mean,Fig. 2. Linearity experiment for the cobas e 601 system according to CLSI EP6 guidelines.
Twenty-three dilution series were prepared by mixing a high concentrated sample pool
with a lowconcentrated sample pool. Three replicates of eachdilution stepwere subsequent-
ly measured in one analytical run on each system and are displayed for each concentration.
Observed values were plotted against the expected values.
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from these data.
2.8. Repeatability and intermediate imprecision according to CLSI EP5-A2
The precision experiment was performed onMODULAR ANALYTICS
E 170, cobas e 411 and cobas e 601 systems, respectively. Repeatability
and intermediate imprecision were determined during 21 days measur-
ing each sample material in two runs per day in duplicate measurement
(n = 84) [25]. Repeatability and intermediate precision was calculated
for each analyzer and sample based on a variance-components model
taking repeatability, run-to-run and day-to-day variance components
into account. Repeatability and intermediate imprecision were
investigated using two levels of quality control material (PreciControl
AMH 1 and 2) and ﬁve levels of spiked serum pool material covering
the lower and upper measuring interval. The spiked serum material
was provided to the sites in frozen aliquots.
2.9. Functional sensitivity
Functional sensitivity was assessed onMODULAR ANALYTICS E 170,
cobas e 411 and cobas e 601 systems, respectively. Each laboratory
pooled low concentration native AMH serum samples targeting ﬁve
concentration ranges below 0.1 ng/ml (0.7 pmol/L). For 10 days, one
aliquot per sample pool was measured in one analytical run. The mean
of each serum pool level was then plotted against the CV and the data
ﬁtted to an exponential curve. The lowest analyte concentration that
can be reproducibly measured with an inter-assay CV of ≤20% was
derived from the ﬁtted equation.
2.10. Linearity
Linearitywas assessed according to CLSI EP6 guidelines. Two laborato-
ries collected native serum sample material in order to generate a high
and a very low concentration AMH sample pool. Twenty-three dilutions
were prepared bymixing the high concentration sample pool (exceeding
the upper measuring range) with the low concentration sample pool
(below measuring range). Three replicates of each dilution step were
subsequently analyzed in one analytical run on oneMODULAR ANALYT-
ICS E 170, cobas e 411 and cobas e 601 systems each. Observed values
were plotted against the expected values and a regressionmodel was se-
lected according to CLSI EP6-A [26].
2.11. Method comparison
Anonymized left-over serum samples from routine diagnostic testing
were used for comparing Elecsys® AMH assay against AMHGen II ELISA,
modiﬁed version (Beckman Coulter Inc., USA, catalog number A79765,
lot numbers 327449 and 325128).
The presented method comparison combines data measured at four
laboratories usingmaterial from at least 250 subjects per site, with 1729
serum samples in total. Data were analyzed using both Passing-Bablok
and weighted Deming regressions.
2.12. Reference interval groups
Samples from 887 female subjects were collected from self-reported
and apparently healthy donors between 20 and 50 years, with regular
menstrual cycles (length 21–35 days). Subjects with a BMI exceeding
30 and/or receiving hormone replacement therapy or using combined
hormonal contraceptives where excluded from the study. Furthermore,
subjects with infertility, gonadal disorder/dysfunction, diagnosed
endometriosis, known previous or current endocrine or metabolic
disorders were excluded. Samples of 149 PCOS-subjects aged 18–
43 years were collected. PCOS was diagnosed according to the
revised diagnostic criteria of PCOS deﬁned by the RotterdamESHRE/ASRM-sponsored PCOS consensus workshop group [20]. Ex-
clusion criteria were hyperprolactinaemia (prolactin N1.23 IU/L),
thyroid dysfunction (thyroid-stimulating hormone outside of 0.35–
5.0 mIU/L), previous gynecological surgery and baseline elevated
serum FSH (FSH N12 IU/L).
3. Results
3.1. Within-run imprecision
Within-run CV for AMH concentrations ranging between 0.24 and
19.2 ng/ml (1.71 to 137 pmol/L) are shown in Fig.1. CV values ranged
between 0.8 and 2.9% for the cobas e 411 analyzers and between 0.7
and 3.4% for cobas e 601/MODULAR ANALYTICS E 170 analyzers.
3.2. Repeatability and intermediate precision according to CLSI EP5-A2
Precision results for AMH concentrations between 0.24 and
19.0 ng/ml (1.71 and136pmol/L) are shown inTable 1. The repeatability
CV values for cobas e 601, cobas e 411 andMODULAR ANALYTICS E 170
immunoanalyzers were respectively 1.2%, 1.8%, and 1.7%. Intermediate
precision CV ranges for cobas e 601, cobas e 411 and MODULAR
ANALYTICS E 170 systems were respectively 2.2%, 4.4%, and 3.5%.
3.3. Functional sensitivity
Functional sensitivity is deﬁned as the lowest analyte concentration
that can be measured with an inter-assay CV of ≤20%. The lowest
concentration sample in this experiment had a mean concentration of
0.021 ng/ml (0.15 pmol/L) on cobas e 601, 0.025 ng/ml (0.18 pmol/L)
on MODULAR ANALYTICS E 170, and 0.026 ng/ml (0.19 pmol/L) on
cobas e 411 and the respective inter-assay CVs were 4.6%, 5.0%, and
4.0%. Therefore, the functional sensitivity of the assay is well below
the limit of quantiﬁcation of 0.03 ng/ml (0.21 pmol/L) provided by the
manufacturer.
3.4. Linearity
Linearity data for the cobas e 601 system are depicted in Fig. 2. In
addition linearity data for the cobas e 411 and MODULAR ANALYTICS
E 170 systems are provided in Supplementary Fig. 1A and B. According
to the selected CLSI EP6-A regression model, the Elecsys® AMH assay
showed linear results in the measuring range of 0.01–23 ng/ml (0.07–
164 pmol/L), the lowest value based on the limit of detection (LOD),
with percentage deviations below 10% for all analyzers.
3.5. Method comparison
The Elecsys® AMH assay was compared to the AMH Gen II ELISA,
modiﬁed version using 1729 serum samples. Passing-Bablok and
weighted Deming regression analyses are shown for all laboratories
and instruments combined in Fig. 3. Although linearity according to
CLSI EP6 regression models were demonstrated for the Elecsys® AMH
assay, the method comparison did not meet the deﬁnition of linearity
over the entiremeasuring range. Therefore an analysis of both the entire
measuring range up to 23 ng/ml (164 pmol/L, top) and an analysis
for AMH values within the normal physiological range, up to 4
ng/ml (28.6 pmol/L, bottom), is presented. The Elecsys® AMH assay
strongly correlates with the AMH Gen II ELISA modiﬁed assay
(Spearman's correlation coefﬁcient 0.987, Pearson's 0.976), but has a
sample recovery of up to 24% less than the AMHGen II ELISA for samples
with concentration ≤4 ng/ml (≤28.6 pmol/L) (applying Passing-Bablok as
regression model). Over the entire measuring range, the Elecsys® AMH
measurements showed up to 28% lower sample concentrations as
compared to the AMH Gen II ELISA modiﬁed version.
Fig. 3. Passing-Bablok and weighted Deming regression analysis between AMH values
measured with the Elecsys® AMH assay and the Beckman AMHGen II ELISA assay modiﬁed
version for all laboratories and instruments combined: (A) for AMH values covering the
whole measuring range (up to 23 ng/ml [164 pmol/L]) and (B) for AMH values within the
normal physiological range, up to 4 ng/ml (28.6 pmol/L).
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assay could measure results in 86 samples (5.0% of all samples) for
which AMH was undetectable using the AMH Gen II ELISA.
3.6. AMH values in healthy women and in polycystic ovary syndrome
(PCOS) patients
AMH values measured in healthy women and in women diagnosed
with PCOS are shown in Table 2 and Fig. 4. In healthy women, median
AMH values declined with increasing age. In women aged 20–24
years, a median AMH concentration of 4.0 ng/ml (28.6 pmol/L) was
observed and in women aged 35–39 years, the median AMHconcentration was 2.00 ng/ml (14.2 pmol/L). Median AMH values in
women diagnosed with PCOS were higher compared to healthy
women and did notmarkedly declinewith increasing age. Inwomen di-
agnosedwith PCOS, amedian of 7.19 ng/ml (51.3 pmol/L)was observed
in subjects aged 20–24 years, and amedian of 6.46 ng/ml (46.1 pmol/L)
was observed in subjects aged 35–39 years.
Discussion
Several studies have shown that AMH is the best biomarker currently
available for ovarian reserve assessment [6,27]. However, the reliability
of commercially available AMH assays has been questioned, which is
hampering the routine clinical use of AMH [14–16]. The results of the
multicenter trial reported here demonstrate excellent analytical perfor-
mance of the ﬁrst fully automated Elecsys® AMH assay.
The AMH Gen II ELISA was reported to be inﬂuenced by pre-
analytical instability [14], and in 2013 Beckman Coulter released an
urgent Field Safety Notice (FSN-20434-3) stating that the AMH Gen
II ELISA was susceptible to complement interference in freshly
drawn and freshly frozen samples. This might have led to artiﬁcially
lower AMH concentration results with a shift of up to 70%, depending
on samples and sample storage conditions. Complement in freshly
drawn samplesmay bind to the Fc portion of the assay capture antibody
of the IgG2a subclass coating the assay wells. The magnitude of the
interference by complement was reported to be dependent on sample
storage conditions and pre-analytical dilution steps [28]. The assay
was subsequently modiﬁed to include a pre-dilution step to eliminate
the complement interference (AMH Gen II ELISA, modiﬁed version).
The Elecsys® AMH assay is based on the same monoclonal antibody
pair as the AMH Gen II ELISA assay however with a different assay
design and technology [17]. Capture and detection antibody bind
preferentially to the mature and pro-region of AMH respectively [29],
and detect AMH in human, bovine and other mammalian species. The
capture antibody reacts with unbound AMH in solution, therefore the
Elecsys® assay is not prone to interference by complement. In a perfor-
mance evaluation study, the Elecsys® AMH assay was unaffected by
sample instability or by different storage conditions for up to 7 days [17].
The analytical performance of the AMH Gen II ELISA was previously
evaluated in a multicenter trial [30]. A functional sensitivity of
0.21 ng/ml (1.50 pmol/L) was observed, and within-batch and
between-batch imprecision measurements assessed over the concen-
tration range of 0.70–9.8 ng/ml (5.00–70.0 pmol/L) were respectively
5.3–11.4% and 3.8–17.3%. By comparison, in the present study the
Elecsys® AMH assay has shown a functional sensitivity at least 7-fold
more sensitive (≤0.03 ng/ml [≤0.21 pmol/L]), and CVs across a wider
measuring range that are consistently lower (CV ≤1.8% for repeatability,
≤4.4% for intermediate precision). Furthermore, the Elecsys® AMH
assay showed linearity across the entire measuring range applying
CLSI EP6 regressionmodels. Therefore, the Elecsys®AMHassay showed
superior technical and inter-laboratory performance as compared to the
AMH Gen II ELISA assay.
The increased sensitivity of the Elecsys® AMH assay allows the
determination of AMH concentration in samples that are undetectable
when using the AMH Gen II ELISA assay. Less sensitive AMH ELISA
methods were previously shown to be of no value following orthotopic
transplantation of ovarian tissue after gonadotoxic treatment [31]. The
improved sensitivity of the Elecsys® AMH assay may thus represent
an important step forward and open up new clinical applications.
Within the scope of this performance evaluation the Elecsys® AMH
assay was compared to the AMH Gen II ELISA modiﬁed version using
1729 anonymized routine samples. AMH values measured by the
Elecsys® AMH assay showed a strong correlation with the AMH Gen II
ELISA modiﬁed assay, but had analyte recovery 24 to 28% lower than
AMH Gen II ELISA modiﬁed version. This conﬁrms method comparison
results between Elecsys® AMH and AMH Gen II ELISAmodiﬁed version
(Passing-Bablok Regression Y = 0.81x -0.046, with n = 57 and r =
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265E. Anckaert et al. / Clinical Biochemistry 49 (2016) 260–2670.98) [32]. However, the observed differences are larger than those
described by van Helden et al. (analyte recovery 12% lower than AMH
Gen II modiﬁed version, with n = 89) [19], possibly due to the high
between-laboratory variability previously described for the AMH Gen
II ELISA assay [15].
The Elecsys® AMH assay was standardized to be traceable to AMH
Gen II ELISA (Beckman Coulter Inc.), unmodiﬁed version. This was
accomplished through sample value transfer from the AMH Gen II
ELISA unmodiﬁed version, using frozen aged serum samples, presumed
to be unaffected by complement interference, covering the entire
measuring range [17]. However, this approach may be limited. Firstly,
high between-laboratory variability has been previously described for
the AMH Gen II ELISA assay [15]. Secondly, aged serum samples might
still be affected by some degree of complement interference. It has
been observed in several publications that the lack of an international
AMH reference material makes comparison between assays difﬁcult
[6,9]. The variability between the two immunoassays reported here,
despite attempts to harmonize the assays, further underscores the
need for development of an international AMH standard and AMH
assay standardization allowing the use of consensual AMH cut-offs.
Reference intervals were determined for Elecsys® AMH to address
the need for an assay-speciﬁc AMH cut-off. In healthy, regularly cycling
women, median AMH decreased from 4.00 ng/ml (28.6 pmol/L) in
women aged 20–24 years to 0.194 ng/ml (1.39 pmol/L) in women
aged 45–50 years. In women diagnosed with PCOS aged 18–43 years,
median AMH values (6.81 ng/ml [48.6 pmol/L]) were elevated in each
age cohort compared to the median AMH values in healthy women.
Two- to four-fold increases in serum AMH have been described previ-
ously in PCOS patients compared to healthy patients [33–36] and we
also observed an approximate two- to four-fold increase. Increasing
evidence suggests that serum AMH measurement has a potential role
in diagnosing PCOS, replacing polycystic ovary morphology assessment
[37,38]. Moreover, AMH levels correlate with PCOS severity [34,39] and
may predict therapeutic responses to clomiphene, or recombinant FSH.
In conclusion, thismulticenter evaluation of theﬁrst fully automated
Elecsys® AMH assay demonstrates excellent analytical performance. In
addition, the AMH reference values determined in this study provide
clinicians with age-dependent reference intervals in a population of
apparently healthy women with regular menstrual cycles, and in
women diagnosed with PCOS. In conjunction with other clinical and
laboratory ﬁndings, the Elecsys® AMH assay is well-suited for the
assessment of ovarian reserve.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.clinbiochem.2015.10.008.
Authors' roles
The manuscript was drafted by EA. SE designed the study. NMPD
contributed literature references and well characterized PCOS
patient samples to the project. EA, MÖ, AG, MCB, CMi, CMü, SE and
CE interpreted study data and critically discussed the study ﬁndings.
JS, AT, DT, FT assayed the samples, performed the data analysis and
interpretation of results. Statistical analysis was performed by CE.
All authors revised the manuscript and approved the ﬁnal version.
Funding
This work was sponsored by Roche Diagnostics GmbH.
Conﬂict of interest
MÖandAGhave receivedﬁnancial beneﬁts for speaking fromRoche.
EA, AT, MCB, NMPD, JS, CMü, DT, FT and CMi have no conﬂict of interest
in relation to this work. CE and SE are employed by Roche Diagnostics
GmbH, which is a manufacturer of in vitro diagnostic products, including
the current Elecsys® AMH assay.
Fig. 4. AMH values measured by the Elecsys® AMH assay in apparently healthy women with regular menstrual cycle of different age groups and in PCOS patients, respectively.
266 E. Anckaert et al. / Clinical Biochemistry 49 (2016) 260–267Acknowledgments
The authors' appreciation goes to the technicians and support staff at
their respective institutions for their contributions to this performance
evaluation and to Alisa Davis and Kim Brown (Roche Diagnostics Inter-
national AG) for editing and revision of the manuscript.References
[1] R.L. Cate, R.J. Mattaliano, C. Hession, R. Tizard, N.M. Farber, A. Cheung, et al., Isolation
of the bovine and human genes for Müllerian inhibiting substance and expression of
the human gene in animal cells, Cell 45 (1986) 685–698.
[2] A.L. Durlinger, P. Kramer, B. Karels, F.H. de Jong, J.T. Uilenbroek, J.A. Grootegoed,
et al., Control of primordial follicle recruitment by anti-Müllerian hormone in the
mouse ovary, Endocrinology 140 (1999) 5789–5796.
[3] I.B. Carlsson, J.E. Scott, J.A. Visser, O. Ritvos, A.P. Themmen,O.Hovatta, Anti-Müllerian
hormone inhibits initiation of growth of human primordial ovarian follicles in vitro,
Hum. Reprod. 21 (2006) 2223–2227.
[4] A.L. Durlinger, M.J. Gruijters, P. Kramer, B. Karels, T.R. Kumar, M.M. Matzuk, et al.,
Anti-Müllerian hormone attenuates the effects of FSH on follicle development in
the mouse ovary, Endocrinology 142 (2001) 4891–4899.
[5] E. Anckaert, J. Smitz, J. Schiettecatte, B.M. Klein, J.C. Arce, The value of anti-Müllerian
hormone measurement in the long GnRH agonist protocol: association with ovarian
response and gonadotrophin-dose adjustments, Hum. Reprod. 27 (2012) 1829–1839.
[6] S.L. Broer, F.J. Broekmans, J.S. Laven, B.C. Fauser, Anti-Müllerian hormone: ovarian
reserve testing and its potential clinical implications, Hum. Reprod. Update 20
(2014) 688–701.
[7] R.A. Anderson, E. Anckaert, E. Bosch, D. Dewailly, C.E. Dunlop, D. Fehr, et al., Prospective
study into the value of the automated Elecsys antimullerian hormone assay for the
assessment of the ovarian growing follicle pool, Fertil. Steril. 103 (2015) 1074–1080
e1074.
[8] S. Iliodromiti, R.A. Anderson, S.M. Nelson, Technical and performance characteristics
of anti-Mullerian hormone and antral follicle count as biomarkers of ovarian
response, Hum. Reprod. Update (2014) 698–710.
[9] S.M. Nelson, R.W. Yates, H. Lyall, M. Jamieson, I. Traynor, M. Gaudoin, et al.,
Anti-Müllerian hormone-based approach to controlled ovarian stimulation for
assisted conception, Hum. Reprod. 24 (2009) 867–875.
[10] R. Fanchin, J. Taieb, D.H. Mendèz Lozano, B. Ducot, R. Frydman, J. Bouyer, High
reproducibility of serum anti-Müllerian hormone measurements suggests a
multi-staged follicular secretion and strengthens its role in the assessment of
ovarian follicular status, Hum. Reprod. 20 (2005) 923–927.
[11] A. La Marca, G. Stabile, A.C. Artenisio, A. Volpe, Serum anti-Müllerian hormone
throughout the human menstrual cycle, Hum. Reprod. 21 (2006) 3103–3107.
[12] NICE (The National Institute for Health and Care Excellence), Fertility: Assessment
and treatment for people with fertility problems, NICE Clinical Guideline, 156, 2013
(Available at: https://www.nice.org.uk/guidance/cg156/resources/guidance-fertility-
pdf [Accessed February 2015]).[13] A.P. Ferraretti, A. La Marca, B.C. Fauser, B. Tarlatzis, G. Nargund, L. Gianaroli, et al.,
ESHRE consensus on the deﬁnition of 'poor response' to ovarian stimulation for
in vitro fertilization: the Bologna criteria, Hum. Reprod. 26 (2011) 1616–1624.
[14] O. Rustamov, A. Smith, S.A. Roberts, A.P. Yates, C. Fitzgerald, M. Krishnan, et al.,
Anti-Müllerian hormone: poor assay reproducibility in a large cohort of subjects
suggests sample instability, Hum. Reprod. 27 (2012) 3085–3091.
[15] E. Zuvela, M. Walls, P. Matson, Within-laboratory and between-laboratory variability
in themeasurement of anti-Müllerian hormone determinedwithin an external quality
assurance scheme, Reprod. Biol. 13 (2013) 255–257.
[16] C.A. Clark, C.A. Laskin, K. Cadesky, Anti-Müllerian hormone: reality check, Hum.
Reprod. 29 (2014) 184–185.
[17] D. Gassner, R. Jung, First fully automated immunoassay for anti-Müllerian hormone,
Clin. Chem. Lab. Med. 52 (2014) 1143–1152.
[18] S.M. Nelson, E. Pastuszek, G. Kloss, I. Malinowska, J. Liss, A. Lukaszuk, et al., Two new
automated, compared with two enzyme-linked immunosorbent, antimullerian
hormone assays, Fertil. Steril. 104 (2015) 1016–1021.e6.
[19] J. van Helden, R. Weiskirchen, Performance of the two new fully automated
anti-Mullerian hormone immunoassays compared with the clinical standard
assay, Hum. Reprod. 30 (2015) 1918–1926.
[20] The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, Revised
2003 consensus on diagnostics criteria and long-term health risks related to
polycystic ovary syndrome (PCOS), Hum. Reprod. 19 (2004) 41–47.
[21] D. Dewailly, M.E. Lujan, E. Carmina, M.I. Cedars, J. Laven, R.J. Norman, et al., Deﬁnition
and signiﬁcance of polycystic ovarianmorphology: a task force report from the Andro-
gen Excess and Polycystic Ovary Syndrome Society, Hum. Reprod. Update 20 (2014)
334–352.
[22] J. Henny, The IFCC recommendations for determining reference intervals: strengths
and limitations, J. Lab. Med. 33 (2009) 45–51.
[23] A. Kunst, A. Busse Grawitz, W. Engeldinger, W. Koch, H. Luthe, W. Stockmann,
Wincaev — a new program supporting evaluations of reagents and analysers, Clin.
Chim. Acta 355 (2005) S361.
[24] G.J. Hahn, W.G. Meeker, Statistical Intervals: A Guide for Practitioners, 1st edn.
Wiley, New York, 1991.
[25] CLSI (Clinical and Laboratory Standards Institute, formerly NCCLS), Evaluation of
precision performance of quantitative measurement methods: approved guideline,
second edition, NCCLS document EP5-A2 24 (2004) 25.
[26] CLSI (Clinical and Laboratory Standards Institute, formerly NCCLS), Evaluation of the
linearity of quantitative measurement procedures: a statistical approach; approved
guideline NCCLS document EP6-A, 23 (2003) 16.
[27] D. Dewailly, C.Y. Andersen, A. Balen, F. Broekmans, N. Dilaver, R. Fanchin, et al., The
physiology and clinical utility of anti-Mullerian hormone in women, Hum. Reprod.
Update 20 (2014) 370–385.
[28] X. Han,M.McShane, R. Sahertian, C.White, W. Ledger, Pre-mixing serum samples with
assay buffer is a prerequisite for reproducible anti-Müllerian hormone measurement
using the Beckman Coulter Gen II assay, Hum. Reprod. 29 (2014) 1042–1048.
[29] N. di Clemente, S.P. Jamin, A. Lugovskoy, P. Carmillo, C. Ehrenfels, J.Y. Picard, et al.,
Processing of anti-Müllerian hormone regulates receptor activation by a mechanism
distinct from TGF-β, Mol. Endocrinol. 24 (2010) 2193–2206.
[30] A.M. Wallace, S.A. Faye, R. Fleming, S.M. Nelson, A multicentre evaluation of the new
Beckman Coulter anti-Müllerian hormone immunoassay (AMH Gen II), Ann. Clin.
Biochem. 48 (2011) 370–373.
267E. Anckaert et al. / Clinical Biochemistry 49 (2016) 260–267[31] F. Janse, J. Donnez, E. Anckaert, F.H. de Jong, B.C. Fauser, M.M. Dolmans, Limited
value of ovarian function markers following orthotopic transplantation of ovarian
tissue after gonadotoxic treatment, J. Clin. Endocrinol. Metab. 96 (2011) 1136–1144.
[32] V. Klemt, V. Hofmann, D. Gassner, First fully automated immunoassay for
anti-Müllerian hormone (AMH) on the cobas e analyzers, Eur. Soc. Hum. Reprod.
Embryol. 29 (Suppl. 1) (2014) 555 (Available at: http://www.eshre2014.eu/~/media/
Files/Munich/ESHRE_2014_ABSTRACT%20BOOK_opt.pdf [Accessed February 2015]).
[33] P. Pigny, E. Merlen, Y. Robert, C. Cortet-Rudelli, C. Decanter, S. Jonard, et al., Elevated
serum level of anti-Müllerian hormone in patients with polycystic ovary syndrome:
relationship to the ovarian follicle excess and to the follicular arrest, J. Clin.
Endocrinol. Metab. 88 (2003) 5957–5962.
[34] J.S. Laven, A.G. Mulders, J.A. Visser, A.P. Themmen, F.H. de Jong, B.C. Fauser,
Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory
women of reproductive age, J. Clin. Endocrinol. Metab. 89 (2004) 318–323.
[35] A.S. Park, M.A. Lawson, S.S. Chuan, S.E. Oberﬁeld, K.M. Hoeger, S.F. Witchel, et al.,
Serum anti-müllerian hormone concentrations are elevated in oligomenorrheic
girls without evidence of hyperandrogenism, J. Clin. Endocrinol. Metab. 95 (2010)
1786–1792.[36] S. Lie Fong, I. Schipper, F.H. de Jong, A.P. Themmen, J.A. Visser, J.S. Laven, Serum
anti-Müllerian hormone and inhibin B concentrations are not useful predictors
of ovarian response during ovulation induction treatment with recombinant
follicle-stimulating hormone in women with polycystic ovary syndrome, Fertil.
Steril. 96 (2011) 459–463.
[37] T.B. Eilertsen, E. Vanky, S.M. Carlsen, Anti-Mullerian hormone in the diagnosis
of polycystic ovary syndrome: can morphologic description be replaced? Hum.
Reprod. 27 (2012) 2494–2502.
[38] D. Dewailly, H. Gronier, E. Poncelet, G. Robin, M. Leroy, P. Pigny, et al., Diagnosis of
polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count
on ultrasound and of the serum AMH level for the deﬁnition of polycystic ovaries,
Hum. Reprod. 26 (2011) 3123–3129.
[39] A. Piouka, D. Farmakiotis, I. Katsikis, D. Macut, S. Gerou, D. Panidis, Anti-Müllerian
hormone levels reﬂect severity of PCOS but are negatively inﬂuenced by obesity:
relationship with increased luteinizing hormone levels, Am. J. Physiol. Endocrinol.
Metab. 296 (2009) E238–E243.
